Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.

about

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

P2860

Q57175832-2C24A1A2-1B70-471B-AEE4-EB0A7A9A8490

P2860

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.

Item

http://www.wikidata.org/entity/Q55381932

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Identifying Circulating Tumor ...... nts with Multiline Resistance.

@en

Identifying Circulating Tumor ...... nts with Multiline Resistance.

@nl

type

Item

label

Identifying Circulating Tumor ...... nts with Multiline Resistance.

@en

Identifying Circulating Tumor ...... nts with Multiline Resistance.

@nl

prefLabel

Identifying Circulating Tumor ...... nts with Multiline Resistance.

@en

Identifying Circulating Tumor ...... nts with Multiline Resistance.

@nl

P1476

Identifying Circulating Tumor ...... nts with Multiline Resistance.

@en

P2093

Can Tian

http://www.w3.org/2001/XMLSchema#string

Huawu Xiao

http://www.w3.org/2001/XMLSchema#string

Hui Wu

http://www.w3.org/2001/XMLSchema#string

Jianxiang Gao

http://www.w3.org/2001/XMLSchema#string

Jing Li

http://www.w3.org/2001/XMLSchema#string

Jun Lu

http://www.w3.org/2001/XMLSchema#string

Lianpeng Chang

http://www.w3.org/2001/XMLSchema#string

Liping Liu

http://www.w3.org/2001/XMLSchema#string

Mengjia Xiao

http://www.w3.org/2001/XMLSchema#string

Min Cao

http://www.w3.org/2001/XMLSchema#string

P2860

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.

A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

P304

111-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EBIOM.2018.05.015

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29807833

http://www.w3.org/2001/XMLSchema#string

P932

6020712

http://www.w3.org/2001/XMLSchema#string

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.

about

P2860

P2860

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932